BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Trauner M, Fuchs CD. Novel therapeutic targets for cholestatic and fatty liver disease. Gut 2022;71:194-209. [PMID: 34615727 DOI: 10.1136/gutjnl-2021-324305] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Puengel T, Liu H, Guillot A, Heymann F, Tacke F, Peiseler M. Nuclear Receptors Linking Metabolism, Inflammation, and Fibrosis in Nonalcoholic Fatty Liver Disease. Int J Mol Sci 2022;23:2668. [PMID: 35269812 DOI: 10.3390/ijms23052668] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
2 European Association for the Study of the Liver. Electronic address: jhepatology@easloffice.eu., European Association for the Study of the Liver. EASL Clinical Practice Guidelines on Sclerosing Cholangitis. J Hepatol 2022:S0168-8278(22)00326-9. [PMID: 35738507 DOI: 10.1016/j.jhep.2022.05.011] [Reference Citation Analysis]
3 Yan M, Hou L, Cai Y, Wang H, Ma Y, Geng Q, Jiang W, Tang W. Effects of Intestinal FXR-Related Molecules on Intestinal Mucosal Barriers in Biliary Tract Obstruction. Front Pharmacol 2022;13:906452. [DOI: 10.3389/fphar.2022.906452] [Reference Citation Analysis]
4 Teng T, Qiu S, Zhao Y, Zhao S, Sun D, Hou L, Li Y, Zhou K, Yu X, Yang C, Li Y. Pathogenesis and Therapeutic Strategies Related to Non-Alcoholic Fatty Liver Disease. Int J Mol Sci 2022;23:7841. [PMID: 35887189 DOI: 10.3390/ijms23147841] [Reference Citation Analysis]
5 Hsu S, Chen H. The first new drug for progressive familial intrahepatic cholestasis. The Lancet Gastroenterology & Hepatology 2022. [DOI: 10.1016/s2468-1253(22)00158-3] [Reference Citation Analysis]
6 Kimura M, Nishikawa K, Osawa Y, Imamura J, Yamaji K, Harada K, Yatsuhashi H, Murata K, Miura K, Tanaka A, Kanto T, Kohara M, Kamisawa T, Kimura K. Inhibition of CBP/β-catenin signaling ameliorated fibrosis in cholestatic liver disease. Hepatol Commun 2022. [PMID: 35855613 DOI: 10.1002/hep4.2043] [Reference Citation Analysis]
7 Peiseler M, Schwabe R, Hampe J, Kubes P, Heikenwälder M, Tacke F. Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease - novel insights into cellular communication circuits. J Hepatol 2022:S0168-8278(22)00375-0. [PMID: 35750137 DOI: 10.1016/j.jhep.2022.06.012] [Reference Citation Analysis]
8 Tanaka N, Honda A. Pemafibrate for primary biliary cholangitis with dyslipidemia: A proposal of a new treatment from Japan. Hepatol Res 2022;52:495-6. [PMID: 35642712 DOI: 10.1111/hepr.13770] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Paternostro R, Trauner M. Current treatment of non-alcoholic fatty liver disease. J Intern Med 2022. [PMID: 35796150 DOI: 10.1111/joim.13531] [Reference Citation Analysis]